According to a research report published this morning, Citi has increased Praxair's PX PT from $120 to $130.
In the report, Citi said, "A better than expected 1Q12 EPS highlights PX's operational consistency, with steady volume growth of 4% and robust operating margins of 22%. Results in North America were particularly impressive as volumes were strong (+7%), compared to its major competitor APD which reported weaker volumes. New plant startups will increasingly support volumes & EPS growth, with new projects contributing $800mm of sales in 2013. We remain fans of PX's strong execution, and raise our TP to $130."
Citi maintains its Buy rating on Praxair, which closed yesterday at $113.77.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in